|
| Tuesday, August 16, 2022 |
|
|
Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company has developed a Peptide Docking Vehicle (PDoV(TM)) to achieve a peptide-enhanced GalNAc platform for siRNA drug delivery. more info >> |
|
| Tuesday, July 26, 2022 |
|
|
Sirnaomics RNAi候选药物STP705用于治疗肝癌的I期临床研究IND申请已获台湾卫生福利部批准 |
| Sirnaomics Ltd.（“公司”，“Sirnaomics”，股份代号：2257.HK），是一家行业领先的专注于探索及开发RNAi疗法的生物制药公司。 more info >> |
|
|
Sirnaomics RNAi候選藥物STP705用於治療肝癌的I期臨床研究IND申請已獲台灣衛生福利部批准 |
| Sirnaomics Ltd.（「公司」，「Sirnaomics」，股份代號：2257.HK），是一家行業領先的專注於探索及開發RNAi療法的生物製藥公司。 more info >> |
|
|
Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics more info >> |
|
| Tuesday, June 21, 2022 |
|
|
Sirnaomics于第四届RNA疗法：从概念到临床专题讨论会上汇报其专有的GalAhead™双靶点RNAi疗法的最新进展 |
| Sirnaomics Ltd.（“公司”，“Sirnaomics”，股份代号：2257.HK），是一家行业领先的专注于探索及开发RNAi疗法的生物制药公司。 more info >> |
|
|
Sirnaomics於第四屆RNA療法：從概念到臨床專題討論會上匯報其專有的GalAhead™雙靶點RNAi療法的最新進展 |
| Sirnaomics Ltd.（「公司」，「Sirnaomics」，股份代號：2257.HK），是一家行業領先的專注於探索及開發RNAi療法的生物製藥公司。 more info >> |
|
|
Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead(TM) Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company's Chief Technology Officer more info >> |
|
| Thursday, June 16, 2022 |
|
|
Sirnaomics于同行评审刊物《皮肤病药物杂志》发表公司核心产品 STP705治疗成人原位鳞状细胞皮肤癌临床研究结果 |
| Sirnaomics Ltd.（“Sirnaomics”，股份代号：2257.HK），是一家行业领先的专注于探索及开发RNAi疗法的生物制药公司。 more info >> |
|
|
Sirnaomics於同行評審刊物《皮膚病藥物雜誌》發表公司核心產品 STP705治療成人原位鱗狀細胞皮膚癌臨床研究結果 |
| Sirnaomics Ltd.（「Sirnaomics」，股份代號：2257.HK），是一家行業領先的專注於探索及開發RNAi療法的生物製藥公司。 more info >> |
|
|
Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology |
| Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the peer-reviewed publication of Phase IIa clinical study results of its lead therapeutic candidate, STP705, for the treatment of skin cancer, in the May 2022 issue of the Journal of Drugs in Dermatology (the "JDD"). more info >> |
|
|
|
|
